Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis.
Cortes J, Calvo V, Ramírez-Merino N, O'Shaughnessy J, Brufsky A, Robert N, Vidal M, Muñoz E, Perez J, Dawood S, Saura C, Di Cosimo S, González-Martín A, Bellet M, Silva OE, Miles D, Llombart A, Baselga J. Cortes J, et al. Among authors: llombart a. Ann Oncol. 2012 May;23(5):1130-1137. doi: 10.1093/annonc/mdr432. Epub 2011 Oct 4. Ann Oncol. 2012. PMID: 21976387 Free article. Review.
Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.
Baselga J, Manikhas A, Cortés J, Llombart A, Roman L, Semiglazov VF, Byakhov M, Lokanatha D, Forenza S, Goldfarb RH, Matera J, Azarnia N, Hudis CA, Rozencweig M. Baselga J, et al. Among authors: llombart a. Ann Oncol. 2014 Mar;25(3):592-598. doi: 10.1093/annonc/mdt543. Epub 2014 Jan 8. Ann Oncol. 2014. PMID: 24401928 Free PMC article. Clinical Trial.
Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis.
Cortes J, Calvo V, Ramírez-Merino N, O'Shaughnessy J, Brufsky A, Robert N, Vidal M, Muñoz E, Perez J, Dawood S, Saura C, Di Cosimo S, González-Martín A, Bellet M, Silva OE, Miles D, Llombart A, Baselga J. Cortes J, et al. Among authors: llombart a. Ann Oncol. 2019 Jul 1;30(7):1179. doi: 10.1093/annonc/mdy535. Ann Oncol. 2019. PMID: 30624662 Free article. No abstract available.
Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study.
Gil-Gil MJ, Bellet M, Morales S, Ojeda B, Manso L, Mesia C, Garcia-Martínez E, Martinez-Jáñez N, Melé M, Llombart A, Pernas S, Villagrasa P, Blasco C, Baselga J. Gil-Gil MJ, et al. Among authors: llombart a. Breast Cancer Res Treat. 2015 Jun;151(3):597-606. doi: 10.1007/s10549-015-3415-2. Epub 2015 May 16. Breast Cancer Res Treat. 2015. PMID: 25981896 Clinical Trial.
Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM).
Colomer R, Alba E, González-Martin A, Paz-Ares L, Martín M, Llombart A, Rodríguez Lescure Á, Salvador J, Albanell J, Isla D, Lomas M, Rodríguez CA, Trigo JM, Germà JR, Bellmunt J, Tabernero J, Rosell R, Aranda E, Cubedo R, Baselga J; Spanish Society of Medical Oncology. Colomer R, et al. Among authors: llombart a. Ann Oncol. 2010 Feb;21(2):195-198. doi: 10.1093/annonc/mdp595. Ann Oncol. 2010. PMID: 20110291 Free PMC article. No abstract available.
Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.
Baselga J, Manikhas A, Cortés J, Llombart A, Roman L, Semiglazov VF, Byakhov M, Lokanatha D, Forenza S, Goldfarb RH, Matera J, Azarnia N, Hudis CA, Rozencweig M. Baselga J, et al. Among authors: llombart a. Ann Oncol. 2019 Jun 1;30(6):1017. doi: 10.1093/annonc/mdy529. Ann Oncol. 2019. PMID: 30624616 Free PMC article. No abstract available.
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.
Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, von Minckwitz G, Sleeboom HP, Forbes J, Barrios C, Frassoldati A, Campbell I, Paija O, Martin N, Modi A, Bundred N. Coleman R, et al. Among authors: llombart a. Ann Oncol. 2013 Feb;24(2):398-405. doi: 10.1093/annonc/mds277. Epub 2012 Oct 9. Ann Oncol. 2013. PMID: 23047045 Free article. Clinical Trial.
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA; TEXT and SOFT Investigators; International Breast Cancer Study Group. Pagani O, et al. N Engl J Med. 2014 Jul 10;371(2):107-18. doi: 10.1056/NEJMoa1404037. Epub 2014 Jun 1. N Engl J Med. 2014. PMID: 24881463 Free PMC article. Clinical Trial.
Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry.
Bartsch R, Frings S, Marty M, Awada A, Berghoff AS, Conte P, Dickin S, Enzmann H, Gnant M, Hasmann M, Hendriks HR, Llombart A, Massacesi C, von Minckwitz G, Penault-Llorca F, Scaltriti M, Yarden Y, Zwierzina H, Zielinski CC; Biotherapy Development Association (BDA). Bartsch R, et al. Among authors: llombart a. Ann Oncol. 2014 Apr;25(4):773-780. doi: 10.1093/annonc/mdt531. Epub 2013 Dec 18. Ann Oncol. 2014. PMID: 24351401 Free article.
128 results